François Bompart
A5013531792- COVID-19 Clinical Research Studies
- Ethics in Clinical Research
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Antimicrobial Resistance in Staphylococcus
- Global Health and Surgery
- Biomedical Ethics and Regulation
- Bacterial Identification and Susceptibility Testing
- COVID-19 and Mental Health
- Pneumonia and Respiratory Infections
- Health Systems, Economic Evaluations, Quality of Life
- Intensive Care Unit Cognitive Disorders
- Ethics in medical practice
- Malaria Research and Control
- Viral Infections and Immunology Research
- Diabetes and associated disorders
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Respiratory Support and Mechanisms
- SARS-CoV-2 detection and testing
- Antibiotics Pharmacokinetics and Efficacy
- Viral gastroenteritis research and epidemiology
- Ocular Infections and Treatments
- Sepsis Diagnosis and Treatment
Inserm
2022-2025
Drugs for Neglected Diseases Initiative
2020-2024
Johns Hopkins Hospital
2024
University of Oxford
2021
Sanofi (France)
2007-2011
Institut Pasteur
2005
University of Pittsburgh Medical Center
2001
Institut Cochin
1991
UCL Australia
1988
Middlesex Hospital
1986
A progressive increase in the incidence of vancomycin resistance strains Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Quinupristin/dalfopristin (Synercid), first injectable streptogramin antibiotic, is active vitro against VREF, an MIC90 1.0 mg/L. We studied clinical efficacy and safety quinupristin/dalfopristin VREF infection. Two prospective studies were conducted simultaneously. The enrolled only...
Abstract Background The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships age, sex, and nationality to presenting symptoms. Methods International, 60 109 symptomatic laboratory-confirmed COVID-19 recruited from 43 countries between 30 January 3 August 2020. Logistic regression was performed evaluate age sex published case definitions most commonly reported Results ‘Typical’ symptoms fever (69%), cough...
Abstract Although it is known that coronavirus disease 2019 can present with a range of neurological manifestations and in-hospital complications, sparse data exist on whether these initial symptoms are closely associated post-acute sequelae SARS-CoV-2 (severe acute respiratory syndrome 2; PANSC) female versus male sex impacts symptom resolution. In this international, multi-centre, prospective, observational study across 407 sites from 15 countries (30 January 2020 to 30 April 2022), we...
Abstract Little is known on the association between clinical factors and coronavirus disease 2019 (COVID‐19) more than 15 days after diagnosis. We conducted a multicentric prospective cohort of COVID‐19 hospitalized patients to describe clinical, biological, virological characteristics at hospital admission over time, according mortality up Day 60 admission. For analysis risk survival, analyses assessing associations demographic or comorbidities were performed using Cox regression model....
Abstract Background Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time COVID-19 as well efficiency novel variants are poorly characterized. Methods In this prospective study, sera of 107 patients hospitalized with were collected at 3 and 6 months postinfection. We performed quantitative neutralization...
Clinicians caring for patients with vancomycin-resistant Enterococcus faecium (VREF) infections face severe constraints in the selection of treatment. Quinupristin/dalfopristin (Synercid) is active vitro against VREF, a MIC90 1.0 μg/mL. We investigated clinical efficacy and safety this agent multicenter, prospective, noncomparative, emergency-use study 396 patients. Patients were included if they had signs symptoms infection, including bacteremia unknown origin, intra-abdominal skin...
Background In low-income and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection.The combination of ravidasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, sofosbuvir has shown efficacy safety in patients with chronic HCV genotype 4 infection.STORM-C-1 trial aimed assess the ravidasvir plus diverse population adults chronically infected HCV.Methods STORM-C-1 is two-stage, open-label, phase 2/3 single-arm...
This case study describes how a public-private partnership initiated to develop new anti-malarial combination, ASAQ Winthrop, has evolved over time address issues posed by its effective deployment in the field. In 2002, DNDi created FACT project two fixed-dose combinations, artesunate-amodiaquine and artesunate-mefloquine, meet WHO treatment recommendations international regulatory agencies approval standards. Sanofi-aventis had started development programme for combination of artesunate...
Developing countries face numerous barriers to conducting effective and efficient ethics reviews of international collaborative research. In addition potentially overlooking important scientific ethical considerations, inadequate or insufficiently trained committees may insist on unwarranted changes protocols that can impair a study's validity. Moreover, poorly functioning review systems impose substantial delays the commencement research, which needlessly undermine development new...
Abstract: Healthy volunteers (HVs) who participate in clinical trials are a vulnerable group that deserves specific protection. We assessed the number and types of studies involve HVs around world outline methodological barriers to their analysis. found tens thousands involved every year large variety countries overwhelming majority not “first-in-human” but pharmacokinetic studies. The two cornerstones for both ethical safe participation properly obtained informed consent minimization...
Hundreds of clinical trials potential treatments and vaccines for the “coronavirus 19 disease” (COVID-19) have been set up in record time. This is a remarkable reaction to global pandemic, but absence coordination research efforts raises serious ethical concerns. Some COVID-19 patients might carry burden trial involvement even though their cannot be completed as researchers are competing patients. A shortage medicines can occur when existing drugs diverted trials. Research ethics committees...
Study Objective. To review the liver histopathology in transplant recipients who developed hyperbilirubinemia during therapy with quinupristin‐dalfopristin, a new streptogramin antibiotic, and to ascertain whether objective histologic evidence of adverse drug effect could be correlated serum bilirubin levels. Design. Retrospective analysis. Setting. University Pittsburgh Medical Center. Patients. From database 34 received quinupristin‐dalfopristin for vancomycin‐resistant Enterococcus...